📊 PLUR Key Takeaways
Is Pluri Inc. (PLUR) a Good Investment?
Pluri exhibits critical financial distress with negative stockholders' equity (-$18.6M), severe liquidity constraints (0.33x current ratio), and a cash runway of approximately one month given $15.8M annual cash burn against $3.4M in reserves. The company generates minimal revenue ($681K) while operating at massive losses, indicating pre-commercialization stage with insufficient capital to reach profitability.
Pluri Inc. Key Strengths (PLUR)
- Positive gross margin of 37.7% demonstrates some operational efficiency at unit level
- Biotech sector exposure offers potential for high-margin products upon successful commercialization
- Modest long-term debt of $1.3M limits leverage risk
PLUR Stock Risks: Pluri Inc. Investment Risks
- Negative stockholders' equity of -$18.6M indicates technical insolvency and balance sheet deterioration
- Critical liquidity crisis: current ratio of 0.33x with monthly cash burn exceeding available reserves
- Operating losses of $19.4M on $681K revenue shows no viable path to profitability without major capital infusion
- Revenue completely stagnant (0% YoY growth) with losses accelerating relative to top line
- Operating and net cash flows deeply negative, burning capital at unsustainable rate
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Revenue growth and new product commercialization milestones
- Capital raise activities and dilution impact
- Path to operating cash flow breakeven
Pluri Inc. (PLUR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PLUR Profit Margin, ROE & Profitability Analysis
PLUR vs Healthcare Sector: How Pluri Inc. Compares
How Pluri Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pluri Inc. Stock Overvalued? PLUR Valuation Analysis 2026
Based on fundamental analysis, Pluri Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pluri Inc. Balance Sheet: PLUR Debt, Cash & Liquidity
PLUR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pluri Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.99 indicates the company is currently unprofitable.
PLUR Revenue Growth, EPS Growth & YoY Performance
PLUR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $167.0K | -$5.5M | $-0.55 |
| Q2 2026 | $185.0K | -$3.0M | $-0.53 |
| Q1 2026 | $316.0K | -$5.9M | $-0.65 |
| Q3 2025 | $71.0K | -$5.3M | $-0.94 |
| Q2 2025 | $105.0K | -$3.0M | $-0.53 |
| Q1 2025 | $54.0K | -$5.0M | $-0.96 |
| Q3 2024 | $71.0K | -$5.3M | $-1.01 |
| Q2 2024 | $2.0K | -$4.9M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pluri Inc. Dividends, Buybacks & Capital Allocation
PLUR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pluri Inc. (CIK: 0001158780)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLUR
What is the AI rating for PLUR?
Pluri Inc. (PLUR) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLUR's key strengths?
Claude: Positive gross margin of 37.7% demonstrates some operational efficiency at unit level. Biotech sector exposure offers potential for high-margin products upon successful commercialization.
What are the risks of investing in PLUR?
Claude: Negative stockholders' equity of -$18.6M indicates technical insolvency and balance sheet deterioration. Critical liquidity crisis: current ratio of 0.33x with monthly cash burn exceeding available reserves.
What is PLUR's revenue and growth?
Pluri Inc. reported revenue of $681.0K.
Does PLUR pay dividends?
Pluri Inc. does not currently pay dividends.
Where can I find PLUR SEC filings?
Official SEC filings for Pluri Inc. (CIK: 0001158780) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLUR's EPS?
Pluri Inc. has a diluted EPS of $-1.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PLUR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Pluri Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PLUR stock overvalued or undervalued?
Valuation metrics for PLUR: ROE of N/A (sector avg: 15%), net margin of -2,634.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PLUR's AI grade for 2026?
Our dual AI analysis gives Pluri Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLUR's free cash flow?
Pluri Inc.'s operating cash flow is $-15.1M, with capital expenditures of $607.0K. FCF margin is -2,313.1%.
How does PLUR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,634.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.33 (avg: 2).